Wells Fargo & Company Unicycive Therapeutics, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.83 - $1.79 $2 - $5	3 Added 1.55%	196 $0
Q4 2023 Feb 09, 2024	BUY	$0.49 - $0.92 $75 - $141	154 Added 394.87%	193 $0
Q3 2023 Nov 13, 2023	SELL	$0.61 - $1.31 $6 - $13	-10 Reduced 20.41%	39 $0
Q2 2023 Aug 15, 2023	BUY	$1.24 - $2.23 $2 - $4	2 Added 4.26%	49 $0
Q1 2023 May 12, 2023	BUY	$0.44 - $2.68 $0 - $2	1 Added 2.17%	47 $0
Q4 2022 Feb 13, 2023	BUY	$0.5 - $0.78 $0 - $0	1 Added 2.22%	46 $0
Q3 2022 Nov 14, 2022	BUY	$0.57 - $0.9 $5 - $8	9 Added 25.0%	45 $0
Q2 2022 Aug 12, 2022	BUY	$0.7 - $1.33 $2 - $3	3 Added 9.09%	36 $0
Q1 2022 May 16, 2022	BUY	$1.07 - $2.28 $1 - $2	1 Added 3.13%	33 $0
Q3 2021 Nov 15, 2021	BUY	$2.47 - $5.85 $79 - $187	32 New	32 $0

46.8M

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $10.5M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.